Pasar al contenido principal

MEJORA DE LA SALUD HUMANA Y ANIMAL A TRAVES DE ESTUDIOS ESTRUCTURALES Y FUNCIONALES DE LAS INTERACCIONES VIRUS-HUESPED Y ENSEMBLAJE VIRAL

RTI2018-095700-B-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2018
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario ASOCIACION CENTRO DE INVESTIGACION COOP EN BIOCIENCIAS CIC BIOGUNE

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Bacteriophage PRD1 as a nanoscaffold for drug loading

  • Duyvesteyn, Helen M. E.
  • Santos-Pérez, Isaac
  • Peccati, Francesca
  • Martínez-Castillo, Ane
  • Walter, Thomas S.
  • Reguera, David
  • Goñi, Félix M.
  • Jiménez-Osés, Gonzalo
  • Oksanen, Hanna M.
  • Stuart, David I.
  • Abrescia, Nicola G. A.
Viruses are very attractive biomaterials owing to their capability as nanocarriers of genetic material. Efforts have been made to functionalize self-assembling viral protein capsids on their exterior or interior to selectively take up different payloads. PRD1 is a double-stranded DNA bacteriophage comprising an icosahedral protein outer capsid and an inner lipidic vesicle. Here, we report the three-dimensional structure of PRD1 in complex with the antipsychotic drug chlorpromazine (CPZ) by cryo-electron microscopy. We show that the jellyrolls of the viral major capsid protein P3, protruding outwards from the capsid shell, serve as scaffolds for loading heterocyclic CPZ molecules. Additional X-ray studies and molecular dynamics simulations show the binding modes and organization of CPZ molecules when complexed with P3 only and onto the virion surface. Collectively, we provide a proof of concept for the possible use of the lattice-like organisation and the quasi-symmetric morphology of virus capsomers for loading heterocyclic drugs with defined properties., This study was supported by the Agencia Estatal de Investigacion (Spain) for project RTI2018-095700-B-I00 (NGAA), for project RTI2018-099592-B-C22 (GJO), and for project FEDER MINECO PGC2018-099857-B-I00 (FMG) and by the Basque Departamento de Educación, Política Lingüística y Cultura for projects PRE_2016_2_0151 (ISP), PRE_2018_1_0102 (AM-C) and IT1264-19 (FMG). DR and NGAA are members of the Spanish Network of Excellence in Physical Virology – FIS2017-90701-REDT. We also thank the Agencia Estatal de Investigacion for the Severo Ochoa Excellence Accreditation to the CIC bioGUNE (SEV-2016-0644). HMED was supported by Wellcome (Grant: ALR00750). DIS was supported by the MRC (MR/N00065X/1)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Immunization with a small fragment of the Schmallenberg virus nucleoprotein highly conserved across the Orthobunyaviruses of the Simbu serogroup reduces viremia in SBV challenged IFNAR<sup>-/-</sup> mice

  • Guerra, Gabriel Soares
  • Barriales, Diego
  • Lorenzo, Gema
  • Moreno, Sandra
  • Anguita, Juan
  • Brun Torres, Alejandro
  • Abrescia, Nicola G.A.
10 Pág., Schmallenberg Virus (SBV), an arbovirus from the Peribunyaviridae family and Orthobunyavirus genus, was discovered in late 2011 in Germany and has been circulating in Europe, Asia and Africa ever since. The virus causes a disease associated with ruminants that includes fever, fetal malformation, drop in milk production, diarrhoea and stillbirths, becoming a burden for small and large farms. Building on previous studies on SBV nucleoprotein (SBV-N) as a promising vaccine candidate, we have investigated the possible protein regions responsible for protection. Based on selective truncation of domains designed from the available crystal structure of the SBV-N, we identified both the N-terminal domain (N-term; Met1 – Thr133) and a smaller fragment within (C4; Met1 – Ala58) as vaccine prototypes. Two injections of the N-term and C4 polypeptides protected mice knockout for type I interferon (IFN) receptors (IFNAR-/-) challenged with virulent SBV, opposite to control groups that presented severe signs of morbidity and weight loss. Viremia analyses along with the presence of IFN-γ secreted from splenocytes re-stimulated with the N-terminal region of the protein corroborate that these two portions of SBV-N can be employed as subunit vaccines. Apart from both proteinaceous fragments being easily produced in bacterial cells, the C4 polypeptide shares a high sequence homology (∼87.1 %) with the corresponding region of nucleoproteins of several viruses of the Simbu serogroup, a group of Orthobunyaviruses that comprises SBV and veterinary pathogens like Akabane virus and human infecting viruses like Oropouche. Thus, we propose that this smaller fragment is better suited for vaccine nanoparticle formulation, and it paves the way to further research with other related Orthobunyaviruses., This work was supported by the Spanish Ministerio de Ciencia, Innovación y Universidades RTI2018-095700-B-I00 (NGAA), RTI2018-096494-B-I00 (JA), AGL2017-83226 (AB) and “La Caixa” Foundation (ID 100010434) INPhINIT “La Caixa” fellowship LCF/BQ/DI19/11730041 (GSG and NGAA)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Four principles to establish a universal virus taxonomy

  • Simmonds, Peter
  • Adriaenssens, Evelien M.
  • Murilo Zerbini, F.
  • Elena, Santiago F.
et al., A universal taxonomy of viruses is essential for a comprehensive view of the virus world and for communicating the complicated evolutionary relationships among viruses. However, there are major differences in the conceptualisation and approaches to virus classification and nomenclature among virologists, clinicians, agronomists, and other interested parties. Here, we provide recommendations to guide the construction of a coherent and comprehensive virus taxonomy, based on expert scientific consensus. Firstly, assignments of viruses should be congruent with the best attainable reconstruction of their evolutionary histories, i.e., taxa should be monophyletic. This fundamental principle for classification of viruses is currently included in the International Committee on Taxonomy of Viruses (ICTV) code only for the rank of species. Secondly, phenotypic and ecological properties of viruses may inform, but not override, evolutionary relatedness in the placement of ranks. Thirdly, alternative classifications that consider phenotypic attributes, such as being vector-borne (e.g., "arboviruses"), infecting a certain type of host (e.g., "mycoviruses," "bacteriophages") or displaying specific pathogenicity (e.g., "human immunodeficiency viruses"), may serve important clinical and regulatory purposes but often create polyphyletic categories that do not reflect evolutionary relationships. Nevertheless, such classifications ought to be maintained if they serve the needs of specific communities or play a practical clinical or regulatory role. However, they should not be considered or called taxonomies. Finally, while an evolution-based framework enables viruses discovered by metagenomics to be incorporated into the ICTV taxonomy, there are essential requirements for quality control of the sequence data used for these assignments. Combined, these four principles will enable future development and expansion of virus taxonomy as the true evolutionary diversity of viruses becomes apparent., The workshop and D.B.S. were funded by a Wellcome Biomedical Resource grant to P.S. and S.S. (WT108418AIA). M.M.P. acknowledges funding from the Academy of Finland (grant 331627) and the Sigrid Jusélius Foundation. E.V.K. is supported by the Intramural Research Program of the US National Institutes of Health (NIH) National Library of Medicine. This work was supported in part through Laulima Government Solutions, LLC prime contract with the US National Institute of Allergy and Infectious Diseases (NIAID) under Contract No. HHSN272201800013C. J.H.K. performed this work as an employee of Tunnell Government Services (TGS), a subcontractor of Laulima Government Solutions, LLC under Contract No. HHSN272201800013C. N.G.A.A. and S.F.E. are supported by the Agencia Estatal de Investigación (Spain) projects RTI2018-095700-B-I00 and PID2019-103998GB-I00, respectively. A.R.M. is a Program Director at the US National Science Foundation (NSF), but the statements and opinions expressed herein are made in the personal capacity and do not constitute the endorsement by NSF or the government of the USA. E.M.A. is supported by the Biotechnology and Biological Sciences Research Council (BBSRC); under the BBSRC Institute Strategic Program Gut Microbes and Health BB/R012490/1 and its constituent projects BBS/E/F/000PR10353 and BBS/E/F/000PR10356. D.L.R. acknowledges support of the United Kingdom Medical Research Council (MC_UU_1201412). S.S. acknowledges support from the Mississippi Agricultural and Forestry Experiment Station (MAFES), USDA-ARS project 58-6066-9-033, and the National Institute of Food and Agriculture, US Department of Agriculture, Hatch Project, under Accession Number 1021494. J.M. is supported by Science Foundation Ireland under Grant Numbers 20/FFP-P/8664 and 15/SIRG/3430. N.V. acknowledges support in part by grants U01 AI151807 and R24 AI120942 from the US NIH. H.M.O. was supported by University of Helsinki funding for FINStruct and Instruct-ERIC research infrastructure. T.S. acknowledges support from the Austrian Science Fund (Grant Number P 28183). The work conducted by the US Department of Energy (DOE) Joint Genome Institute (S.R.), a DOE Office of Science User Facility, is supported by the Office of Science of the U.S. Department of Energy operated under Contract No. DE-AC02-05CH11231. S.D. acknowledges support from the US National Science Foundation (DEB 1453241, OIA 1545553). B.E.D. was supported by the European Research Council (ERC) Consolidator grant 865694-DiversiPHI and the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy – EXC 2051 – Project-ID 390713860, and the Alexander von Humboldt Foundation in the context of an Alexander von Humboldt-Professorship founded by German Federal Ministry of Education and Research. A.K. was supported by the ERC Consolidator grant 101001623-PALVIREVOL. J.M.K was supported by Deutsche Forschungsgemeinschaft within “Sonderforschungsbereich TRR 51”. E.J.L. was supported by the NIH NIAID under Award Number U24AI162625. C.L. was supported by a Postdoctoral Mandate (PDMt2/21/038) from the KU Leuven Research Council and a fellowship (12D8623N) from the Research Foundation – Flanders (FWO). M.B.S. was supported by the US National Science Foundation awards OCE#1829831 and ABI#1759874. Y.B. was supported by the Professional Association of the Alliance of International Science Organizations (ANSO-PA-2020-07) and the Open Biodiversity and Health Big Data Programme of IUBS., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A novel Schmallenberg virus subunit vaccine candidate protects IFNAR-/- mice against virulent SBV challenge

  • Boshra, Hani
  • Lorenzo, Gema
  • Charro, Diego
  • Moreno, Sandra
  • Guerra, Gabriel Soares
  • Sánchez, Isbene
  • Garrido, Joseba M.
  • Geijo, Mariví
  • Brun Torres, Alejandro
  • Abrescia, Nicola G.A.
9 Pág., Schmallenberg virus (SBV), an arthropod-transmitted pathogenic bunyavirus, continues to be a threat to the European livestock industry, causing morbidity and mortality among young ruminant livestock. Here, we describe a novel SBV subunit vaccine, based on bacterially expressed SBV nucleoprotein (SBV-N) administered with a veterinary-grade Saponin adjuvant. When assayed in an IFNAR-/- mouse model, SBV-N with Saponin induced strong non-neutralizing broadly virus-reactive antibodies, decreased clinical signs, as well as significantly reduced viremia. Vaccination assays also suggest that this level of immune protection is cell mediated, as evidenced by the lack of neutralizing antibodies, as well as interferon-γ secretion observed in vitro. Therefore, based on these results, bacterially expressed SBV-N, co-administered with veterinary-grade Saponin adjuvant may serve as a promising economical alternative to current SBV vaccines, and warrant further evaluation in large ruminant animal models. Moreover, we propose that this strategy may be applicable to other bunyaviruses., This work was supported by the Marie Sklodowska Curie Actions programme number MSCAIF-EF-ST-660155 (H.B. and N.G.A.A.), the Spanish Ministerio de Ciencia, Innovación y Universidades RTI2018-095700-B-I00 (N.G.A.A.), AGL2017-83226R (A.B.), the Basque Departamento de Desarrollo Económico e Infraestructura 37-2017-00036 (N.G.A.A.) and “La Caixa” Foundation (ID 100010434) INPhINIT “La Caixa” fellowship LCF/BQ/DI19/11730041 (G.S.G. and N.G.A.A.). MICINN is also thanked for the Severo Ochoa Excellence Accreditation to the CIC bioGUNE (SEV-2016-0644)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

SUMOylation controls Hu antigen R posttranscriptional activity in liver cancer

  • Lachiondo-Ortega, Sofía
  • Rejano-Gordillo, Claudia María
  • Simón, Jorge
  • Lopitz-Otsoa, Fernando
  • Delgado, Teresa C.
  • Mazan-Mamczarz, Krystyna
  • Goikoetxea-Usandizaga, Naroa
  • Zapata-Pavas, L. Estefanía
  • García-del Río, Ana
  • Guerra, Pietro
  • Peña-Sanfélix, Patricia
  • Hermán-Sánchez, Natalia
  • Al-Abdulla, Ruba
  • Fernández-Rodríguez, Carmen
  • Azkargorta, Mikel
  • Velázquez-Cruz, Alejandro
  • Guyon, Joris
  • Martín, César
  • Zalamea, Juan Diego
  • Egia-Mendikute, Leire
  • Sanz-Parra, Arantza
  • Serrano-Maciá, Marina
  • González-Recio, Irene
  • Gonzalez-López, Monika
  • Martínez-Cruz, Luis Alfonso
  • Pontisso, Patrizia
  • Aransay, Ana M.
  • Barrio, Rosa
  • Sutherland, James D.
  • Abrescia, Nicola G. A.
  • Elortza, Félix
  • Lujambio, Amaia
  • Banales, Jesús M.
  • Luque, Raúl M.
  • Gahete, Manuel D.
  • Palazón, Asís
  • Ávila, Matías A.
  • Marín, José J. G.
  • De, Supriyo
  • Daubon, Thomas
  • Diaz-Quintana, Antonio
  • Díaz-Moreno, Irene
  • Gorospe, Myriam
  • Rodríguez, Manuel S.
  • Martínez-Chantar, María Luz
© 2024 The Author(s). This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)., The posttranslational modification of proteins critically influences many biological processes and is a key mechanism that regulates the function of the RNA-binding protein Hu antigen R (HuR), a hub in liver cancer. Here, we show that HuR is SUMOylated in the tumor sections of patients with hepatocellular carcinoma in contrast to the surrounding tissue, as well as in human cell line and mouse models of the disease. SUMOylation of HuR promotes major cancer hallmarks, namely proliferation and invasion, whereas the absence of HuR SUMOylation results in a senescent phenotype with dysfunctional mitochondria and endoplasmic reticulum. Mechanistically, SUMOylation induces a structural rearrangement of the RNA recognition motifs that modulates HuR binding affinity to its target RNAs, further modifying the transcriptomic profile toward hepatic tumor progression. Overall, SUMOylation constitutes a mechanism of HuR regulation that could be potentially exploited as a therapeutic strategy for liver cancer., This work was supported by grants to M.L.M.-C. from Departamento de Industria del Gobierno Vasco, Spain; Ministerio de Ciencia e Innovación, Spain (grant no. PID2020-117116RB-I00); European Regional Development Fund (ERDF), EU; and CIBERehd, which is funded by Instituto de Salud Carlos III (ISCIII), Spain. M.L.M.-C. and J.S. received funding from Ministerio de Ciencia e Innovación (grant no. RTC2019-007125-1) and ISCIII (grant no. DTS20/00138). M.L.M.-C. and R.M.L. acknowledge Ministerio de Ciencia e Innovación (grant no. RED2022-134397-T). M.L.M.-C. and J.M.B. were awarded with a grant from Fundación la Caixa, Spain (grant no. HR17-00601). M.L.M.-C., J.M.B., M.A.A., and J.J.G.M. acknowledge financial support from Fundación Científica de la Asociación Española Contra el Cáncer (AECC), Spain. M.S.R. recognizes funding from Fondo Sectorial de Investigación SRE - CONACYT, Mexico (grant no. 0280365); Horizon 2020 Research and Innovation Program funded under Marie Skłodowska-Curie Actions, EU (grant no. 765445); and REPÈRE and Programme de Prématuration from Région Occitanie, France. M.G., S.D., and K.M.-M. were supported by the National Institute on Aging (NIA), National Institutes of Health (NIH), US (grant no. Z01-AG000511-23). I.D.-M. is grateful for the grants received from Junta de Andalucía, Spain (grant no. BIO-198, US-1254317, P18-FR-3487, and P18-HO-4091); Ministerio de Ciencia, Innovación y Universidades, Spain (grant no. PGC2018-096049-BI00); and Fundación Ramón Areces, Spain. T.D. acknowledges Fondation ARC, France (grant no. 208084). J.J.G.M. was supported by Junta de Castilla y León, Spain (grant no. SA063P17); Fundación La Marató TV3, Spain (grant no. 201916-31); ISCIII (grant no. PI19/00819); CIBERehd; and ERDF (grant no. OLD-HEPAMARKER). M.A.A. recognizes Gobierno de Navarra, Spain (grant no. GºNa 42/21); Eurorregión Nueva Aquitania-Euskadi-Navarra, Spain; Ministerio de Ciencia e Innovación (grant no. PID2019-104878RB-I00); and CIBERehd. A.P. expresses gratitude to the European Research Council (ERC), EU (grant no. 804236) for their support. M.D.G. received financial support from Junta de Andalucía (grant no. PEMP-0036-2020 and BIO-0139); Ministerio de Universidades, Spain (grant no. FPU20/03957); ISCIII (grant no. PI20/01301), Fundación Sociedad Española de Endocrinología y Nutrición (FSEEN), Spain; CIBERehd; and CIBERobn, which is also funded by ISCIII. J.M.B. acknowledges Euskadi RIS3 (grant no. 2019222054, 2020333010, and 2021333003) and Elkartek programs from Gobierno Vasco (grant no. KK-2020/00008); ISCIII (grant no. PI18/01075, CPII19/00008, and PI21/00922); CIBERehd; PSC Support, UK; AMMF The Cholangiocarcinoma Charity, UK (grant no. EU/2019/AMMFt/001); Horizon 2020 Research and Innovation Program (grant no. 825510); ERDF; and PSC Partners Seeking a Cure, US. A.L. received financial support from the Damon Runyon-Rachleff Innovation Award, US (grant no. DR52-18) and the MERIT Award (R37) from the National Cancer Institute (NCI), NIH (grant no. R37CA230636). F.E. expresses his gratitude to ProteoRed from ISCIII (grant no. PT13/0001/0027) and CIBERehd. N.G.A.A. was funded by Ministerio de Ciencia, Innovación y Universidades (grant no. RTI2018-095700-B-I00). R.B. acknowledges financial support from Gobierno Vasco (grant no. IT1165-19); Ministerio de Economía, Industria y Competitividad, Spain (grant no. SAF2017-90900-REDT); Ministerio de Economía, Industria y Competitividad, ERDF (grant no. BFU2017-84653-P); Ministerio de Ciencia e Innovación (grant no. PID2020-114178GB-I00); and Horizon 2020 funded under Marie Skłodowska-Curie Actions (grant no. 765445-EU). A.M.A. acknowledges CIBERehd. L.A.M.-C. obtained grants from Ministerio de Economía y Competitividad (grant no. CSD2008-00005); Ministerio de Economía, Industria y Competitividad (grant no. BFU2016-77408-R); ISCIII; and EJP RD, EU (grant no. EJPRD19-040). I.G.-R. was supported by Ministerio de Economía, Industria y Competitividad (grant no. BES-2017-080435 ). M.S.-M. is grateful to the AECC, Sede de Bizkaia, Spain for the financial support. J.D.Z. was awarded with a grant from Ministerio de Economía, Industria y Competitividad (grant no. SEV-2016-0644-18-2). C.M. acknowledges Gobierno Vasco (grant no. IT-1264-19) and Ministerio de Ciencia e Innovación (grant no. PID2022-136788OB-I00). A.V.-C. was supported by Ministerio de Educación, Cultura y Deporte, Spain (grant no. FPU016/01513). C.F.-R. thanks Tekniker, Spain and CIC bioGUNE, Spain for financial support. A.G.-d.R. was funded by Bikaintek program from Gobierno Vasco (grant no. 48-AF-W1-2019-00012). N.G.-U. obtained a grant from Gobierno Vasco. T.C.D. expresses gratitude to AECC. J.S. received financial support from CIBERehd. C.M.R.-G. was supported by Ayudas a la Recualificación Margarita Salas from Universidad de Extremadura, Ministerio de Universidades financed by NextGenerationEU., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

pH-antenna residues trigger a large-scale conformational change in the large extracellular loop domain of the CD81 human receptor

  • Risueño, Cristina
  • Carbajo, Irene
  • Charro, D.
  • Abrescia, N. G.
  • Coluzza, Ivan
CD81 is a human receptor that clusters into microdomains to mediate cell signaling processes. Previous structural studies on the CD81 large-extracellular-loop domain (CD81LEL) proposed that its conformation (ranging from closed to open) may depend on environmental pH conditions. However, the precise mechanism governing CD81LEL plasticity has remained unconfirmed until now. Here, by combining molecular dynamics simulations and spectroscopic experiments on CD81LEL, we show that the mechanism underlying the dependence of the changes in pH to the opening of CD81LEL relates to the modulation of the solvation shell by “antenna” residues. The antenna residues are D139 and E188. Under acidic conditions, such residues generate a signal cascade propagating through the CD81LEL molecule changing the local solvation that, in turn, acts as an effector of the closed-to-open conformational transition. We further proved the key role of D139 and E188 by introducing mutations that switch off their sensitivity to pH. As expected, the mutations stabilize the closed conformation. This signal transduction mechanism might play a role in other cellular receptors that function along the endosomal pathway., We acknowledge the computer resources at Tirant and technical support provided by the Spanish Supercomputing Network (Grant No. BCV-2019-2-0007). We also acknowledge the support of the computing infrastructure of the i2BASQUE academic network. This research was supported by the Spanish Ministerio de Ciencia, Innovación y Universidades (Grant Nos. RTI2018-095700-B-I00 and PID2021-126130OB-I00 to N.G.A.A.) and by the CIC bioGUNE and CIC biomaGUNE (Grant No. CICBMG-PhD-2018-02296 to CRF). MCIN is also acknowledged for the Severo Ochoa Excellence Accreditation to the CIC bioGUNE (Grant No. CEX2021-001136-S)., With funding from the Spanish government through the "Severo Ochoa Centre of Excellence" accreditation (CEX2021-001136-S)., Peer reviewed